NASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis $23.79 +0.29 (+1.23%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About ArriVent BioPharma Stock (NASDAQ:AVBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ArriVent BioPharma alerts:Sign Up Key Stats Today's Range$23.00▼$24.2850-Day Range$20.43▼$28.0152-Week Range$14.35▼$30.99Volume195,305 shsAverage Volume177,766 shsMarket Capitalization$796.82 millionP/E RatioN/ADividend YieldN/APrice Target$36.80Consensus RatingBuy Company OverviewArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Read More… Solar Energy: What Donald Trump, Elon Musk, and the DNC All Agree On (Ad)Find out how one NASDAQ-listed company is poised to tackle the home energy crisis, bringing a unique solution to soaring costs - one that's already being delivered to thousands of homes across North America... And sought after by some of the world's most valuable companies, including Fortune 100-listed Honeywell International.GET THE FULL REPORT NOW ArriVent BioPharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScoreAVBP MarketRank™: ArriVent BioPharma scored higher than 30% of companies evaluated by MarketBeat, and ranked 879th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArriVent BioPharma has only been the subject of 4 research reports in the past 90 days.Read more about ArriVent BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ArriVent BioPharma are expected to decrease in the coming year, from ($3.03) to ($3.20) per share.Read more about ArriVent BioPharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.58% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in ArriVent BioPharma has recently increased by 13.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.58% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in ArriVent BioPharma has recently increased by 13.41%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.88 News SentimentArriVent BioPharma has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ArriVent BioPharma this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 9.48% of the stock of ArriVent BioPharma is held by institutions.Read more about ArriVent BioPharma's insider trading history. Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AVBP Stock News HeadlinesArriVent BioPharma, Inc. (NASDAQ:AVBP) Sees Large Increase in Short InterestSeptember 30 at 12:34 PM | americanbankingnews.comBuy Rating for ArriVent BioPharma Backed by Firmonernib’s Efficacy in NSCLC TrialsSeptember 24, 2024 | markets.businessinsider.comNext Week Elon Could Trigger a Boom in this Sub-$3 Stock Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world… October 1, 2024 | InvestorPlace (Ad)ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6%September 23, 2024 | americanbankingnews.comBiocureTechInc (CURE-X.CN)September 20, 2024 | finance.yahoo.comArriVent BioPharma: Bringing A Novel Cancer Drug From ChinaSeptember 18, 2024 | seekingalpha.comAnalyst boosts ArriVent BioPharma shares price target after promising trial dataSeptember 12, 2024 | uk.investing.comArriVent BioPharma stock target raised on positive trial resultsSeptember 12, 2024 | investing.comSee More Headlines AVBP Stock Analysis - Frequently Asked Questions How have AVBP shares performed this year? ArriVent BioPharma's stock was trading at $20.00 on January 1st, 2024. Since then, AVBP shares have increased by 19.0% and is now trading at $23.79. View the best growth stocks for 2024 here. How were ArriVent BioPharma's earnings last quarter? ArriVent BioPharma, Inc. (NASDAQ:AVBP) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.65) earnings per share for the quarter, meeting the consensus estimate of ($0.65). When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an initial public offering (IPO) on Friday, January 26th 2024. The company issued 9,722,222 shares at $18.00 per share. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today10/01/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CUSIPN/A CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$36.80 High Stock Price Target$39.00 Low Stock Price Target$35.00 Potential Upside/Downside+57.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio25.50 Quick Ratio25.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.79) per share Price / Book-4.89Miscellaneous Outstanding Shares33,494,000Free FloatN/AMarket Cap$784.09 million OptionableN/A BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:AVBP) was last updated on 10/1/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredSolar Energy: What Donald Trump, Elon Musk, and the DNC All Agree OnFind out how one NASDAQ-listed company is poised to tackle the home energy crisis, bringing a unique solution ...The Tomorrow Investor | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredCentral Bank Abandons USDBillionaire investors are pouring capital into gold at rates never seen before… But what these wealthy "fat...True Gold Republic | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.